Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.42 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2467842 | 0.84 | MTNR1A (0.46) | MTNR1AMTNR1BSMN1; SMN2NPSR1GRM7 | |
| SCHEMBL19797799 | 0.84 | MTNR1A (0.46) | MTNR1AMTNR1BSMN1; SMN2NPSR1GRM7 | |
| SCHEMBL7273542 | 0.83 | MTNR1A (0.53) | MTNR1AMTNR1BSMN1; SMN2NPSR1PDPK1 | |
| SCHEMBL11138133 | 0.83 | MTNR1A (0.53) | MTNR1AMTNR1BSMN1; SMN2NPSR1PDPK1 | |
| SCHEMBL7270673 | 0.83 | MTNR1A (0.53) | MTNR1AMTNR1BSMN1; SMN2NPSR1PDPK1 | |
| SCHEMBL23772365 | 0.83 | MTNR1A (0.53) | MTNR1AMTNR1BSMN1; SMN2NPSR1PDPK1 | |
| SCHEMBL9854709 | 0.79 | MTNR1A (0.49) | MTNR1AMTNR1BSMN1; SMN2NPSR1PDPK1 | |
| SCHEMBL9854682 | 0.79 | MTNR1A (0.53) | MTNR1AMTNR1BSMN1; SMN2NPSR1PDPK1 | |
| SCHEMBL11748227 | 0.79 | IDO1 (0.44) | PDPK1CA1CA2 | |
| SCHEMBL2466144 | 0.78 | PDPK1 (0.61) | MTNR1AMTNR1BPDPK1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4782252-B2 | — | — | 2011-09-28 | — | — | JP | claimed |
| EP-0738149-B1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMA (IL) | 2006-11-29 | — | — | EP | claimed |
| US-20020068839-A1 | COMPOSITIONS CONTAINING AND METHODS OF USING 1-AMINOINDAN AND DERIVATIVES THEREOF AND PROCESS FOR PREPARING OPTICALLY ACTIVE 1-AMINOINDAN DERIVATIVES | COHEN SASSON (IL) | 2002-06-06 | — | — | US | claimed |
| US-6271263-B1 | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2001-08-07 | — | — | US | claimed |
| US-5994408-A | THERAPY FOR PARKINSON'S DISEASE; ANTICONVULSANT | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-11-30 | — | — | US | claimed |
| EP-0738149-A4 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMA (IL) | 1999-10-27 | — | — | EP | claimed |
| EP-0738149-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1996-10-23 | — | — | EP | claimed |
| WO-1995018617-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-07-13 | — | — | WO | claimed |
| EP-0738149-B1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMA (IL) | 2006-11-29 | — | — | EP | disclosed |
| EP-0951465-B1 | ALPHA-AMINO ACID AMIDES, PREPARATION THEREOF AND THE THERAPEUTICAL USE THEREOF | CHIESI FARMA SPA (IT) | 2003-04-16 | — | — | EP | disclosed |
| US-6528685-B2 | Such as (R)-N-(2-acetamido)-1-aminoindan for treatment of Parkinson's disease, dementia, epilepsy, convulsions, or seizures | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2003-03-04 | — | — | US | disclosed |
| US-20020068839-A1 | COMPOSITIONS CONTAINING AND METHODS OF USING 1-AMINOINDAN AND DERIVATIVES THEREOF AND PROCESS FOR PREPARING OPTICALLY ACTIVE 1-AMINOINDAN DERIVATIVES | COHEN SASSON (IL) | 2002-06-06 | — | — | US | disclosed |
| US-6271263-B1 | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2001-08-07 | — | — | US | disclosed |
| US-6114391-A | A DERIVATIVES OF SERINAMIDE, GLYCINAMIDE, ALANINAMIDE AND PHENYLALANINAMIDE FOR TREATING NEUROLOGICAL DISEASES | CHIESI FARMACEUTICI S.P.A. (IT) | 2000-09-05 | — | — | US | disclosed |
| US-5877218-A | PARKINSON'S DISEASE; ANTIEPILEPSY AGENTS; ANTICONVULSANTS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-03-02 | — | — | US | disclosed |
| US-5877221-A | TREATING DEMENTIA | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-03-02 | — | — | US | disclosed |
| US-5639913-A | TREATMENT OF PARKINSON'S DISEASE, DEMENTIA, EPILEPSY | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1997-06-17 | — | — | US | disclosed |
| EP-0738149-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1996-10-23 | — | — | EP | disclosed |
| WO-1996021640-A1 | OPTICALLY ACTIVE AMINOINDANE DERIVATIVES AND PREPARATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1996-07-18 | — | — | WO | disclosed |
| WO-1995018617-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068839-A1 | COMPOSITIONS CONTAINING AND METHODS OF USING 1-AMINOINDAN AND DERIVATIVES THEREOF AND PROCESS FOR PREPARING OPTICALLY ACTIVE 1-AMINOINDAN DERIVATIVES | PARK7, GAP43, PSEN1 | MTNR1A 135/4885MTNR1B 374/4885SMN1; SMN2 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.